Genomic Health, Inc. (GHDX) Insider Steven Shak Sells 5,500 Shares

Genomic Health, Inc. (NASDAQ:GHDX) insider Steven Shak sold 5,500 shares of the firm’s stock in a transaction dated Monday, June 11th. The stock was sold at an average price of $50.22, for a total value of $276,210.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Steven Shak also recently made the following trade(s):

  • On Wednesday, May 9th, Steven Shak sold 5,500 shares of Genomic Health stock. The stock was sold at an average price of $36.64, for a total value of $201,520.00.

Shares of GHDX traded down $0.83 during mid-day trading on Thursday, hitting $49.27. 14,084 shares of the company’s stock were exchanged, compared to its average volume of 204,894. Genomic Health, Inc. has a fifty-two week low of $26.54 and a fifty-two week high of $53.65. The company has a market capitalization of $1.77 billion, a price-to-earnings ratio of 4,927.00 and a beta of 0.64.

Genomic Health (NASDAQ:GHDX) last announced its earnings results on Wednesday, May 2nd. The medical research company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.08. Genomic Health had a negative net margin of 1.95% and a positive return on equity of 3.15%. The business had revenue of $92.60 million during the quarter, compared to the consensus estimate of $88.95 million. During the same quarter in the prior year, the firm earned ($0.02) earnings per share. The business’s quarterly revenue was up 12.5% compared to the same quarter last year. sell-side analysts forecast that Genomic Health, Inc. will post 0.47 earnings per share for the current fiscal year.

Several equities analysts have issued reports on GHDX shares. ValuEngine raised Genomic Health from a “hold” rating to a “buy” rating in a report on Friday, May 11th. Canaccord Genuity raised their price objective on Genomic Health from $41.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, June 4th. BidaskClub raised Genomic Health from a “hold” rating to a “buy” rating in a report on Friday, March 30th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $33.00 price objective on shares of Genomic Health in a report on Thursday, March 8th. Finally, Deutsche Bank raised their price objective on Genomic Health from $32.00 to $34.00 and gave the stock a “hold” rating in a report on Thursday, May 3rd. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, one has issued a buy rating and three have issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $34.22.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Northern Trust Corp boosted its stake in shares of Genomic Health by 0.6% during the first quarter. Northern Trust Corp now owns 269,424 shares of the medical research company’s stock worth $8,430,000 after buying an additional 1,608 shares during the period. Meeder Asset Management Inc. lifted its position in Genomic Health by 120.7% in the fourth quarter. Meeder Asset Management Inc. now owns 2,960 shares of the medical research company’s stock valued at $101,000 after purchasing an additional 1,619 shares during the period. Allianz Asset Management GmbH lifted its position in Genomic Health by 2.4% in the first quarter. Allianz Asset Management GmbH now owns 77,515 shares of the medical research company’s stock valued at $2,425,000 after purchasing an additional 1,840 shares during the period. Swiss National Bank lifted its position in Genomic Health by 7.1% in the first quarter. Swiss National Bank now owns 36,300 shares of the medical research company’s stock valued at $1,136,000 after purchasing an additional 2,400 shares during the period. Finally, Teachers Advisors LLC lifted its position in Genomic Health by 12.3% in the fourth quarter. Teachers Advisors LLC now owns 39,510 shares of the medical research company’s stock valued at $1,351,000 after purchasing an additional 4,333 shares during the period. Institutional investors and hedge funds own 89.90% of the company’s stock.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply